Abbott Laboratories 2002 Annual Report (10-K) Summary
Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2002, for Abbott Laboratories, an Illinois corporation engaged in the discovery, development, manufacture, and sale of health care products. The company operates through five reporting segments: Pharmaceutical Products, Diagnostic Products, Hospital Products, Ross Products, and International. Abbott also holds a 50% interest in TAP Pharmaceutical Products Inc., a joint venture with Takeda Chemical Industries.
Key Financial Metrics
| Metric | 2002 | 2001 | Change |
|---|---|---|---|
| Net Sales | $17,684.7 million | $16,285.2 million | +8.6% |
| Net Earnings | $2,793.7 million | $1,550.4 million | +80.2% |
| Diluted EPS | $1.78 | $0.99 | +80.8% |
| Gross Profit Margin | 51.9% | 52.4% | -0.5 pts |
| Operating Cash Flow | $4,182.9 million | $3,566.8 million | +17.3% |
| Total Assets | $24,259.1 million | $23,296.4 million | +4.1% |
| Long-Term Debt | $4,274.0 million | $4,335.5 million | -1.4% |
| Working Capital | $2,119.6 million | $492.4 million | +330.5% |
Note: 2001 earnings were significantly depressed by a $1.33 billion pre-tax charge for acquired in-process research and development related to the BASF acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 8.6% year-over-year, driven by volume growth (8.2%) and price increases (1.0%), partially offset by unfavorable foreign exchange rates (-0.6%). The Pharmaceutical and International segments saw the strongest growth.
- Earnings Recovery: The significant increase in net earnings compared to 2001 is largely due to the absence of the massive $1.33 billion in-process R&D charge recorded in 2001. Excluding nonrecurring charges, adjusted diluted EPS was $2.06 in 2002 versus $1.88 in 2001.
- Margin Pressure: Gross profit margins declined slightly to 51.9% due to an FDA consent decree charge ($129 million), restructuring charges ($174 million), and unfavorable product mix, though these were partially offset by the cessation of goodwill amortization under new accounting standards (SFAS 142).
- Liquidity Improvement: Working capital surged from $492 million to over $2.1 billion, primarily due to operating cash flows used to reduce short-term commercial paper borrowings.
Guidance, Outlook, Risks, and Unusual Items
- Unusual Items:
- FDA Consent Decree: A $129 million pre-tax charge was recorded in 2002 due to non-conformance with FDA Quality System Regulations at the Lake County, Illinois diagnostics facility. Additional costs may be incurred if re-inspection fails.
- Restructuring: A $174 million charge was recorded for restructuring plans to align global manufacturing, eliminating 2,600 positions. Expected annual after-tax savings are $80–$100 million.
- Investment Impairments: $211 million in charges related to other-than-temporary declines in the market value of equity securities.
- Legal and Regulatory Risks:
- Enteral Nutrition Investigation: The U.S. Attorney's Office is conducting a civil and criminal investigation into the enteral nutritional business (Ross division). Management believes an adverse outcome could materially affect cash flows and results of operations in a given year but not financial position.
- Patent Litigation: Significant patent expirations are anticipated for clarithromycin (2005) and divalproex sodium (2008). Abbott is defending patents for TriCor against competitors.
- Antitrust and Pricing: Numerous lawsuits and investigations remain pending regarding prescription drug pricing practices (e.g., Lupron, Hytrin) and average wholesale price reporting.
- Outlook:
- New Product Launch: Humira (rheumatoid arthritis) received FDA approval in December 2002, with worldwide sales forecasted to exceed $150 million in 2003.
- Capital Allocation: Abbott plans to purchase the remaining 14.4 million shares of its common stock authorized in 2000, beginning in 2003. Pension funding for the main domestic plan is expected to be $200 million in 2003.
Investor Verification Checklist
- FDA Compliance Status: Verify the outcome of the FDA re-inspection of the Lake County diagnostics facility to assess potential for further charges or revenue restrictions.
- Enteral Nutrition Investigation: Monitor developments in the U.S. Attorney's Office investigation into the Ross division for potential fines or operational impacts.
- Patent Expirations: Track the timeline for clarithromycin (Biaxin) patent expiration in 2005 and the status of TriCor patent litigation.
- Humira Performance: Validate actual sales performance of Humira in 2003 against the $150 million forecast.
- Restructuring Savings: Confirm the realization of the projected $80–$100 million in annual after-tax savings from the 2002 restructuring plans.